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Phthalates represent a large class of chemicals
that are widely used in commercial products.
The potential for human exposure is high
given their use in a vast range of products
including medical packaging, cosmetics, chil-
dren’s toys, wood ﬁnishes, paints, and uphol-
stery (1–5). Although phthalate exposures are
widespread, characterization of human expo-
sure has been limited because of the difﬁculty
of chemical analysis for phthalates.
Animal data suggest a broad spectrum of
health outcomes associated with phthalate
exposure including developmental toxicity
(cleft palate, decreased pup weight, testicular
damage), endocrine disruption (testicular tox-
icity, decreased fertility, decreased sperm
motility, decreased milk synthesis), and car-
cinogenicity (1–3, 6–8). Phthalates differ with
respect to their toxicity. Of the phthalates
most commonly used, diethylhexyl phthalate
(DEHP) and dibutyl phthalate (DBP) and
their metabolites have the greatest potential
toxicity. DEHP suppresses estradiol and ovu-
lation in cycling rats (9), is a reproductive tox-
icant, and is carcinogenic in animal models
(10,11). DBP causes testicular toxicity in rats
through an antiandrogen mechanism (12)
and impairs uterine function, leading to fetal
death and resorption in rats (13). Butyl ben-
zyl phthalate is weakly estrogenic in vitro
(14) and is teratogenic in rodents (15,16). In
2000, the National Toxicology Program’s
Center for the Evaluation of the Risks to
Human Reproduction evaluated seven
phthalates for their potential to cause repro-
ductive harm to humans. One of the main
conclusions from these evaluations was that
more data regarding human exposure were
necessary (6–8). The National Institute of
Occupational Safety and Health (17) has
classiﬁed dibutyl phthalate as a high-priority
chemical for study because of its widespread
use and its reproductive toxicity in animals.
Accurate and reliable biologic markers of
phthalate exposure are necessary to assess
and appropriately classify exposures in
humans. 
Until recently, chemical analysis for
human exposure to phthalates was limited to
highly exposed populations (18,19) because
contamination of samples by laboratory
materials hampered measurements in envi-
ronmentally exposed subjects. A new assay is
available that measures the phthalate
monoester metabolites in urine, reducing the
potential for sample contamination from
laboratory materials (20). Commercial prod-
ucts contain primarily phthalate diesters;
metabolism in biologic systems cleaves one
of the ester groups, producing a phthalate
monoester metabolite (21). The metabolite
is subsequently glucoronidated and excreted
in the urine. In addition to reducing the
potential for contamination, measurement of
monoester metabolites has the added advan-
tage of having longer biologic half-lives (~12
hr) than the diester phthalate (< 3 hr)
(18,19,21). Furthermore, most of the toxicity
is associated with the phthalate monoester.
Population-based samples of U.S. resi-
dents indicate that human exposure to
phthalates is common, particularly to
monobutyl phthalate and monoethyl phtha-
late (22,23). Although the new analytic
method allows accurate determination of
phthalate levels in urine, little is known
about the temporal variability and repro-
ducibility of these measures that affect their
application in epidemiologic studies. To
explore these aspects, we analyzed phthalate
levels in two consecutive ﬁrst morning void
samples from women ages 35–49 years and
assessed their reproducibility. 
Materials and Methods
Subjects. Participants were 46 African-
American women from a randomly selected
sample of members of a prepaid health plan
in Washington, DC. They were participants
in a study to screen for uterine fibroids in
1996–1997. The women ranged in age from
35 to 49 years, with a mean age of 42.3 years
(SD = 3.9). The women selected for this
analysis were not anticipated to have unique
phthalate exposures and were selected to rep-
resent low- and high-income strata of the par-
ent study population. All subjects provided
informed consent prior to participating.
Urine samples. Women provided two
consecutive ﬁrst morning void urine samples
on the second and third days of their men-
strual cycles. Samples were shipped to the
storage laboratory by overnight mail in a
specially designed styrofoam kit that
included a frozen cold pack. Samples were
aliquoted and frozen at –20°C for future
analyses. Urine samples were collected and
stored in plastic containers. These containers
were screened for phthalate monoesters before
the pilot study began, and none contained
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Articles
Phthalates are ubiquitous in our modern environment because of their use in plastics and cosmetic
products. Phthalate monoesters—primarily monoethylhexyl phthalate and monobutyl phthalate—
are reproductive and developmental toxicants in animals. Accurate measures of phthalate exposure
are needed to assess their human health effects. Phthalate monoesters have a biologic half-life of
approximately 12 hr, and little is known about the temporal variability and daily reproducibility of
urinary measures in humans. To explore these aspects, we measured seven phthalate monoesters
and creatinine concentration in two consecutive ﬁrst-morning urine specimens from 46 African-
American women, ages 35–49 years, residing in the Washington, DC, area in 1996–1997. We
measured phthalate monoesters using high-pressure liquid chromatography followed by tandem
mass spectrometry on a triple quadrupole instrument using atmospheric pressure chemical ioniza-
tion. We detected four phthalate monoesters in all subjects, with median levels of 31 ng/mL for
monobenzyl phthalate (mBzP), 53 ng/mL for monobutyl phthalate (mBP), 211 ng/mL for
monoethyl phthalate (mEP), and 7.3 ng/mL for monoethylhexyl phthalate (mEHP). These were
similar to concentrations reported for other populations using spot urine specimens. Phthalate lev-
els did not differ between the two sampling days. The Pearson correlation coefﬁcient between the
concentrations on the 2 days was 0.8 for mBP, 0.7 for mEHP, 0.6 for mEP, and 0.5 for mBzP.
These results suggest that even with the short half-lives of phthalates, women’s patterns of expo-
sure may be sufﬁciently stable to assign an exposure level based on a single ﬁrst morning void urine
measurement. Key words: biologic markers, environmental exposure, phthalates, reliability, urine,
women’s health. Environ Health Perspect 110:515–518 (2002). [Online 3 April 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p515-518hoppin/abstract.htmldetectable levels. This analysis was restricted
to urine samples collected on Tuesdays
through Fridays, to minimize variation asso-
ciated with potential differential exposures on
weekends as compared to weekdays. First
morning voids were used because we
expected these samples to vary less than other
types of urine samples and because they are
generally more concentrated (24).
Laboratory analyses. One 1.2-mL
aliquot of each day’s urine was analyzed. We
included both urine samples from an indi-
vidual in the same laboratory batch to elimi-
nate interset variation. To assess interset
variation in the analysis, at least one quality
assurance sample was included in each batch.
Interset variation (variation across the ana-
lytic batches) was evaluated using all 12
quality assurance samples. Two batches
included three quality assurance samples to
assess intraset variation—that is, variation
within an analytic run. The quality assurance
samples were from a pooled first morning
void sample from women of similar age as
the study population. These quality assur-
ance samples were labeled and handled in an
identical manner to other samples, and the
analytic laboratory staff were unaware of
sample status. All samples were shipped
frozen to the analytic laboratory and
remained frozen until chemical analysis.
We analyzed urine samples for seven
phthalate monoesters using methods
described previously (20,25). The phthalate
monoesters analyzed were monobenzyl
phthalate (mBzP), monobutyl phthalate
(mBP), monocyclohexyl phthalate (mCHP),
monoethyl phthalate (mEP), monoethyl-
hexyl phthalate (mEHP), monoisononyl
phthalate (mINP), and monooctyl phthalate
(mOP). Samples were spiked with 13C4-
labeled phthalate monoesters and 4-methy-
lumbelliferone glucuronide. The samples
were then treated with β-glucuronidase to
release the phthalate monoesters from their
conjugated forms. Deconjugated urine sam-
ples were extracted twice with Oasis
hydrophobic lipophilic balance (Waters
Corp, Milford, MA) solid-phase extraction
and resuspended in mobile phase. Chrom-
atographic separation by high-pressure liquid
chromatography was followed with tandem
mass spectrometry on a triple quadrupole
instrument using atmospheric pressure
chemical ionization (Finnigan Inc., San Jose,
CA). We monitored levels of 4-methylum-
belliferone as quality control for the decon-
jugation step. We analyzed method blanks,
laboratory quality control samples (spiked
human urine), and standards along with the
study urine samples. We measured urinary
creatinine using an ASTRA analzyer
(Beckman Inc., Brea, CA) based on a Jaffe
rate reaction (25). Samples that failed to
meet the laboratory quality assurance criteria
were not included the analysis; as a result,
mEP measurements on 11 subjects and
mINP and creatinine in one sample were
unavailable. 
Statistical analyses. We reported phtha-
late results on the basis of concentration in
urine (nanograms per milliliter) and concen-
tration based on creatinine concentration in
urine (nanograms per gram creatinine). We
used creatinine adjustment to correct for
variation in urine concentration. We con-
ducted statistical analyses on both unad-
justed and creatinine-adjusted phthalate
levels. Nondetected values were assigned a
value of 0 and excluded from analyses of log-
transformed data. Because we were inter-
ested in reproducibility in population
samples, we did not exclude outliers from
any analyses.
Statistical analyses consisted of summary
and descriptive statistics, paired t-tests com-
paring the difference in phthalate levels
between the 2 days, Pearson and Spearman
correlation analyses between the 2 days, and
random effects models to estimate the intra-
class correlation coefficient (ICC) between
the two samples. We calculated the ICC
using random effects models to estimate the
within- and between-subject variance
(26,27). Because the distributions were log-
normally distributed, all analyses requiring a
normality assumption were conducted using
log-transformed data. We estimated reliabil-
ity using the ICC and the number of sam-
ples necessary to obtain 80% reliability was
estimated using the method described by
Fleiss (26). We calculated the percent of
variability associated with the individual as
opposed to the laboratory measurement by
subtracting the observed variability in the
method from the total within-subject vari-
ability and then calculating the percentage of
the total variability explained. All analyses
were conducted using SAS software (SAS
Institute, Cary, NC). 
Results
We detected mEP, mBP, mEHP, and mBzP
in urine samples from all subjects. We found
no signiﬁcant differences in the mean phtha-
late levels between day 1 and day 2 using
paired t-tests (data not shown). Table 1 pre-
sents the average concentrations of the two
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Table 1. Average phthalate and creatinine levels in urine. 
Analyte No.a Mean SD Median Minimum Maximum
Unadjusted phthalates (ng/mL urine)
mBzP 46 39.4 30.0 31.5 5.6 135.2
mBP 46 78.1 58.0 53.0 0.7 251.3
mCHP 46 1.0 3.8 0.3 0.0 26.1
mEP 35 259.8 212.8 211.4 57.9 1042.8
mEHP 46 16.5 30.1 7.3 1.0 143.9
mINP 46 8.1 45.2 0.0 0.0 306.8
mOP 46 4.4 25.5 0.5 0.0 173.7
Creatinine-adjusted phthalates
(µg/g creatinine)
mBzP 46 26.5 18.5 21.6 8.3 119.7
mBP 46 52.7 35.8 43.4 0.4 157.3
mCHP 46 0.6 1.8 0.2 0.0 12.5
mEP 35 183.0 135.3 134.8 32.1 611.1
mEHP 46 12.3 17.4 6.4 0.4 77.3
mINP 45 4.6 25.1 0.0 0.0 169.0
mOP 46 2.1 11.4 0.3 0.0 77.8
Creatinine (mg/dL) 46 150.6 64.7 133.2 66.4 304.9
Based on two consecutive ﬁrst morning void samples from 46 African-American women, Washington, DC, 1996–1997.
aAverage of two measures per subject. If both measures were missing, then they were not included here. Sample results
outside the laboratory quality assurance range were not reported (11 mEP and 1 mINP/creatinine). 
Table 2. Performance of the phthalate analytic method in a general population sample. 
Study samples Quality assurance samples
Samples DL Total < DLb Mean conc Intraset Interset
Analyte analyzeda (ng/mL) No. Percent (ng/mL) CV (%)c CV (%)d
mBzP 92 0.8 1 1 31.2 19 16
mBP 92 0.6 1 1 45.0 11 15
mCHP 92 0.7 70 76 0.5 60 69
mEP 70 1.0 0 0 116.4 16 15
mEHP 92 1.2 5 5 10.2 10 24
mINP 91 0.8 69 76 ND ND ND
mOP 92 0.9 70 76 0.7 62 122
Abbreviations: conc, concentration; DL, detection limit; ND, not determined. Sample: 46 African-American women,
Washington, DC, 1996–1997.
aTwo samples per subject; 22 mEP and 1 mINP samples were outside laboratory quality assurance limits and are not
reported. bTotal number of samples below the DL. cIntraset coefficient of variation, variation within an analytic batch.
dInterset coefﬁcient of variation, variation across the eight analytic batches.samples for each phthalate measured.
Subjects’ mean phthalate concentrations
ranged up to three orders of magnitude,
with monoethyl phthalate detected at the
highest levels of all phthalates analyzed. 
The performance of the analytic method
in this population can be described by the
number of samples below the detection limit
and the performance of quality assurance
samples (Table 2). More than 75% of the
samples analyzed for mCHP, mINP, and
mOP were below the analytic detection
limit. The coefﬁcients of variation (CVs) for
the quality assurance samples were very low
for the common phthalates (mEP, mBP,
mEHP, mBzP) and were high among ana-
lytes that were present at very low concentra-
tions. These CVs were based on our pooled
urine sample, which had phthalate concen-
trations comparable to the population medi-
ans. There were no differences between
intraset and interset CVs, suggesting no
important variation between laboratory
batches. The observed CVs for the quality
assurance samples represent a small portion
of the total variation associated with an indi-
vidual (e.g., within-person error). Even for
chemicals present at low concentration,
96–100% of the observed within-person
variation was associated with the individual
and not with the measurement. Because of
the infrequency of detection of mCHP,
mINP, and mOP, we conducted no further
analysis of these chemicals. 
Correlations between the two measures
of phthalates were good and generally
improved when the results were adjusted for
creatinine concentration (Table 3). The
Spearman correlation coefficients and the
Pearson correlation coefficients for the log-
transformed data yielded similar results.
Figure 1 presents scatter plots between the
two measures for creatinine-adjusted phtha-
late concentrations for all phthalates. We
calculated the ICCs as a measure of reliabil-
ity; these values were similar to those for the
Pearson correlation coefﬁcients because only
two measures per individual were available.
Monobutyl phthalate had the highest esti-
mate of reliability, with an ICC of 0.80
[95% confidence interval (CI), 0.69–0.88].
mEP and mEHP had ICCs ≥ 0.6. Given the
observed variability in the urinary phthalate
measurements, to achieve a reliability of
80%, one sample would be needed to clas-
sify mBP exposure accurately, two samples
for mEHP, three samples for mEP, and four
samples for mBzP.
Discussion
We observed a high degree of reliability for
the four phthalates most commonly detected
in urine. The ICCs for these four creatinine-
adjusted phthalates ranged from 0.53 for
mBzP to 0.80 for mBP. Given that these
metabolites have biologic half-lives of
approximately 12 hr or less in humans and
that exposures can vary from day to day, the
observed ICCs are surprisingly high. We
designed our experiment for the most similar
conditions from one day to the next; thus,
these ICCs may represent the upper bound
for reproducibility as a long-term measure of
phthalate exposure. 
The high ICCs indicate that between-
subject variability is much greater than
within-subject variability. The observed CVs
for the quality assurance samples represent a
small portion of the total variation associated
with an individual’s measurement (e.g.,
within-person error). Laboratory variation
explained less than 4% of the within-subject
variability, suggesting that most intraindivid-
ual variation results from temporal differ-
ences in exposure. Although the ICCs were
not as high as those observed for other envi-
ronmental exposures such as organochlorine
pesticides (28), they were similar to or better
than those observed for nutritional compo-
nents of diet (29). Because dietary nutrients
have substantial daily variation whereas
organochlorines exposure does not, compar-
isons to nutritional data are more relevant.
The success observed for studies of nutritional
elements indicates that the ICCs for phtha-
lates should be sufficient for epidemiologic
studies.
The phthalate concentrations observed
in ﬁrst morning void urine samples collected
from this group of African-American women
in 1996–1997 were similar to those reported
in two large population samples of U.S. resi-
dents (22,23). With the same analytic tech-
nique, phthalate levels were measured in spot
urine samples from 289 adult participants of
the National Health and Nutritional
Examination Survey (NHANES) III col-
lected from 1988 through 1994 and from
1,029 adult participants of NHANES IV
collected in 1999 (22,23). Table 4 lists the
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Table 3. Correlation coefﬁcients and reliability estimates for urinary phthalate measurements. 
Correlation coefﬁcients Reliability
Analyte Spearman Pearsona ICCa 95% CI 
Unadjusted phthalate concentrations
mBzP 0.27 0.34 0.34 0.11–0.54
mBP 0.42 0.62 0.61 0.43–0.74
mEP 0.49 0.47 0.48 0.23–0.67
mEHP 0.59 0.52 0.52 0.32–0.68
Creatinine-adjusted phthalate concentrations
mBzP 0.50 0.53 0.53 0.31–0.69
mBP 0.67 0.83 0.80 0.69–0.88
mEP 0.66 0.59 0.60 0.36–0.76
mEHP 0.71 0.67 0.67 0.49–0.79
Sample: 46 African-American women, Washington, DC, 1996–1997. Nondetected samples were excluded for analyses
using log-transformed data (n = 1 for mBzP, mEHP). 
aUsing log-transformed data. 
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1median values observed in each population.
As with our population, detection of mCHP,
mINP, and mOP was rare. Our group had
moderately higher levels of mEHP, mBzP,
and mBP, but the values were within the
ranges reported for these other groups. In
the NHANES III sample, women of repro-
ductive age had higher levels of mBP, which
is consistent with our data (22). Although
we restricted our population to minimize
variation, our sample appears comparable to
other populations. 
Phthalate exposure is believed to be
ubiquitous given the widespread use of
phthalates in plastics and cosmetic products;
however, little is known about the sources
and patterns of human exposure. Although
exposures are common, these data, along
with the NHANES data, indicate extensive
variation in the level of exposure among
individuals. Reliable biologic markers will
enable application in epidemiologic studies
as well as development of questionnaires that
may identify key predictors of phthalates.
Because the toxicologic properties of phtha-
lates vary, biologic markers may be key to
assessing health effects because the commer-
cial uses of some phthalates may be suffi-
ciently similar that assessing exposure using
questionnaires may be difficult. The ICCs
for the two phthalates of greatest toxicologic
importance, mBP and mEHP, are suffi-
ciently high to warrant application of these
measures in population-based studies.
Our study, designed as a best-case exam-
ple to explore reproducibility of phthalate
levels in urine samples, showed a surprisingly
high degree of reliability in urinary phthalate
levels from one day to the next, suggesting
that women’s phthalate exposure patterns
were relatively stable. We saw no signiﬁcant
differences in phthalate monoester levels
from one day to the next. The levels
observed were similar to concentrations
reported in spot urine samples collected
from the U.S. general population from
1988 through 1999. Although the distribu-
tions of phthalate concentrations in the
general population and our sample appear
similar, whether the reproducibility of ran-
dom spot samples is comparable to that in
first morning void samples is not known.
Additionally, no data were available to deter-
mine how well either of these types of sam-
ples predicts an individual’s exposure over
time. Repeated-measures studies are needed
to address the temporal variation of phtha-
late exposure, both over the course of a day,
a week, and throughout the year. However,
given the good reliability for the four most
common phthalates in this study, these bio-
markers could be useful tools to estimate
human exposure to phthalates, to determine
the sources of phthalate exposure, and to
evaluate potential health effects associated
with exposure.
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Table 4. Median phthalate levels in U.S. population-based samples, 1988–1999. 
Concentration (ng/mL urine)
NHANES III NHANES IV Present study
Phthalate (n = 289) (n = 1,029) (n = 46)
mBP 41.0 27.5 53.0
mBzP 21.2 18.5 31.5
mEP 305.0 171.0 211.4
mEHP 2.7 3.3 7.3
NHANES III: 289 adult participants, 1988–1994, spot urines (22); NHANES IV: 1,029 adult participants, 1999, spot urines
(23); present study: 46 women, DC, 1996–1997, ﬁrst morning voids. All samples measured using same analytic technique.